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Abstract 
 
This study investigates alternatives to current financial accounting treatment of research and de-
velopment expenditures in United States public corporations.  A questionnaire survey was sent to 
members of the Financial Directors Network of the Industrial Research Institute of America, 
representing over forty percent of private research and development in the United States.   Back-
ground research and the survey indicate that if the financial reporting of research and develop-
ment is modified, research and development will increase and a shift from short-term to long-term 
projects will occur; and finally United States public corporations will more effectively compete in 
the international markets. 
 
 
Synopsis and Introduction 
 
he outlook for R&D in 2001 continues to be strong.  In 1998, U.S. R&D grew by 6.5% after adjusting for 
inflation.  However, “Of the top 20 corporations investing in 1998 R&D, only eight will be U.S. firms.  It 
was not long ago that U.S. firms dominated the top 20 list with 15 of the largest of the R&D spenders” 
(Wolff, 2000).  The Council on Competitiveness report states “…the United States is not laying the foun-
dation for its long-term prosperity…based upon R&D statistics” (Council  on Competitiveness, 1999).  “The trend 
away from basic research toward more product development and technical service, first detected in the late 
1980’s…continues” (Wolff, 1994).  Numerous studies with controversial results have investigated the possible ef-
fects of the financial accounting treatment of U.S. R&D expenditures on R&D spending (Dukes, 1980; Elliott, 1984; 
Ball, 1980; Bierman and Dukes, 1975; Braitwaite, 1967).  The forces that influence R&D spending in addition to fi-
nancial accounting are many and varied including management, internal cash flow, capital markets, government pol-
icy and perhaps most important available research projects.  Financial accounting may be becoming less relevant to 
external users and the capitalization of R&D may be useful (Lev and Zarowin, 1999).  In an information based 
economy, R&D should be even more important; however, research discloses in a random sample of the Fortune 500 
companies that R&D as a percent of sales has remained constant from 1986 through 1998 (Compustat Data, 1999).  
Why has R&D not increased in importance to sales?  The effect of the financial accounting of R&D expenditures on 
R&D spending may be part of the answer. 
 
 Historically, expensing versus capitalizing research and development (R&D) expenditures has long been an im-
portant and controversial topic with few popular accounting treatments (Lev and Zarowin, 1999; Nix, 1992; Gellein  
and Newman,  1973;  Wolf, 1989; Marshal,  1980; Newman,  1988; Munson,  1987;  Nixon and  Lonie, 
__________ 
Readers with comments or questions are encouraged to contact the authors via email. 
1990; Guerard, 1987; Selto and Clouse, 1986; Horwitz and Kolodny, 1980; Wolfson, 1980; Higgins, 1954).  The 
mandated accounting treatment, SFAS No. 2, 1974, which requires public corporations to expense R&D expendi-
T 
The Journal of Applied Business Research                                                                  Volume 18, Number 1 
 96 
tures in the period incurred, provides a strong incentive to decrease R&D, because expensed R&D has an immediate 
adverse impact on reported profits.  International business firms do not suffer under this impact which may effect the 
relevancy of financial earnings (Barth and Clinch, 1998; Carnegie and Turner, 1987).  Imagine expensing a plant 
during construction, such as the multi-million dollar Utah chip production plant which never opened in 1999 or 
2000.  The same effect may occur when intangible assets arising from research costs are expensed in the year they 
are incurred.  The mandated expense treatment provides an incentive to spend a disproportionate share of R&D on 
projects that have a short-term rather than long-term return.  Researching a new product frequently requires a 5 to 10 
year investment (Biggadike, 1979).  Traditionally the product life cycle has been even longer.  Thus research plan-
ning influenced by quarterly or annual reported earnings may adversely affect both individual companies as well as 
our national economy.  When a capital asset such as R&D is expensed in the year incurred, reported income is dis-
torted due to a lack of matching of expenditures with related revenue generation (Thomas, 1969).  Prior to 1974, fi-
nancial reporting of R&D expenditures ran the gauntlet between full capitalization in the year incurred versus full 
expensing in the year incurred (SFAS No. 2, 1974).  The impact of tax policy on financial reporting no doubt influ-
enced the passage and acceptance of SFAS No. 2.  The use of a contra stockholders’ equity account in which all 
R&D expenditures would be placed when incurred and then later amortized is a possible compromise solution; im-
mediate write off for tax purposes need not be affected (Raby, 1967; Tax Foundation, 1990).  At the end of each 
year a fixed percent (such as 20%) of what is remaining in the equity account from prior years’ expenditures would 
be charged to R&D expense for the current year.  With this proposed contra stockholder account method, during pe-
riods of increasing R&D expenditures, current R&D expenses would be less than under the required expense-as-
incurred method.  Thus, under the proposal, the current R&D expenditures would be expensed over their future rev-
enue-producing period; but, during periods of decreasing R&D expenditures, current R&D expenses would be 
greater under the proposed method than in current practice.  Again, R&D expenditures are more closely matched to 
their revenue-producing period.  When there is no change in the total R&D expenditures from year to year, current 
R&D expenses would be the same under the proposal and the required expense-as-incurred method.  Thus, R&D 
expenditures would be more closely matched to R&D revenue generated under the proposed contra stockholder eq-
uity account method under all budgeting situations.  The proposal also encourages a shift from short- to long-term 
R&D under all three situations.  (See Illustration of “Contra Stockholder Equity” Approach) 
 
 The use of a contra stockholders’ equity approach is already required and used in accounting for the unrea-
lized loss on long-term marketable securities, the translation gains and losses on foreign currency amounts, the net 
loss not recognized as pension expense and treasury stock transactions (SFAS No. 12, 1975; SFAS No. 52, 1981; 
SFAS No. 87, 1988). 
 
  In the current study members from the Financial Directors Network of the Industrial Research Institute, 
representing over 40 percent of the industrial R&D in the U.S., responded to a questionnaire survey.  Greater than 
50% of those receiving the questionnaire replied in a usable format.  These respondents represent corporations, 
which account for over 20 percent of the corporate R&D spending in the U.S.  The average annual R&D expendi-
tures of these companies are 65% of average annual profits.  When R&D expenditures are 65% of profits, it is easy 
to picture how, under current practice, R&D expenditures may be cut back to boost profit during a profit squeeze. 
 
Results of Questionnaire 
 
 Questions asked referred to the use of such a contra stockholders’ equity account and to what was the most 
appropriate financial disclosure of R&D expenditures in general.  When asked the following question, “After enact-
ment of this proposal, the current year’s expenses would normally be unaffected by the current year’s R&D expendi-
tures.  When current profits are unsatisfactory to higher management, in general, what effect (if any) would the pro-
posed method have on current year R&D expenditures relative to the now required expense as incurred practice?”  
48% indicated that they would increase their current year’s R&D, 12% indicated a decrease, and 40% indicated no 
change.  These results indicate that our present “expense as incurred rule” may well inhibit total R&D expenditures 
in the periods they are most badly needed.  Also, some companies would be affected while many others would not. 
 
 
Illustration of “Contra Stockholder Equity” Approach 
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Accounting information about an unidentified company as of 12/31/99 
(amounts in millions) 
 
R & D Expenditures 1999 1998 1997 1996 1995 1994    
  $600 $590 $580 $560 $530 $480 
 
Tax rate all years:  37% 
 
Pre-tax and pre-R&D amortization income for 1999:  $1,000 
 
Accounting entries required on 12/31/99, if the “contra stockholders’” equity approach to the accounting treatment 
of R&D expenditures were implemented in an unidentified company as of 1/1/99 (amounts in millions): 
 
1. Contra-stockholders Equity       $600 
  Cash               $600 
 (R&D 1999 expenditures) 
 
2. R&D Amortization Expense       $548 
  Contra-stockholders’ equity account        $548 
 (to recognize 1999 R&D amortization expense) 
  1998 1997 1996 1995 1994 
  ($590 + $580 + $560 + $530 + $480 x 20% = $548) 
 
3. Income Tax Expense*                                      $167 
 Income Taxes Payable*                               $148  
 Deferred Tax Liability*                                    $19 
(to recognize tax expense, taxes payable and deferred taxes; a pretax income before R&D    amortization 
expense is assumed to be $1,000) 
 
*Computations: 
 
For financial statement purposes            For computing taxes payable 
 
Income before R&D expense and 
     Taxes are deducted: $1,000 $1,000 
Less R&D amortization expense 548   600 
Taxable income:  542 400 
 
Tax rate:    37% 37% 
Taxes payable:  $167 $148 
 
Deferred tax liability:  $167 – $148 = $19 
 
 When asked the following question, “After enactment of this proposal, what effect (if any) will there be on 
the amount of annual R&D expenditures relative to the amount your firm would have spent each year under the now 
required expense as incurred practice?”  32% answered that R&D expenditures would be increased.  The remaining 
68% replied that there would be no effect.  Once again, we are reminded that the proposed method may have a sig-
nificant impact on increasing R&D expenditures. 
 
 When asked the following question, “After enactment of this proposal, what effect (if any) relative to 
present practice will there be in the amount of long-term R&D expenditures compared to short-term R&D expendi-
tures?  Nearly one-half (44%) of the respondents indicated that there would be an increase in long-term compared to 
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short-term R&D expenditures under the proposed method, while 56% indicated there would be no effect.  United 
States industry has, for many years, been frequently criticized for emphasizing short-term returns at the expense of 
overall long-term benefit.  It is significant that simply by changing the required method of financial reporting, nearly 
one-half of the respondents would spend less of their total R&D budget on short-term projects and more on long-
term.  It is apparent that required financial reporting is influencing corporate financial management to make deci-
sions that conflict with sound R&D management and the long-term benefit of the company. 
 
 A pressing problem in R&D budgeting in many companies is annual fluctuation of R&D expenditures.  
This is certainly due, in part, to keeping short-term financial reported profits stable or positive.  With this is mind, 
respondents were asked the following question:  “After enactment of this proposal, what effect (if any) relative to 
present practice will there be in the annual fluctuations (if any) of R&D expenditures?”  Over one-third (33%) of the 
respondents replied that there would be a decrease in annual fluctuations, 8% indicated an increase, while the re-
maining 56% believed there would be no effect.  We are not suggesting there would not be annual fluctuations in 
R&D expenditures but rather that fluctuations should not be a result of financial reporting requirements which may 
pressure managers to decrease R&D at times when it is most badly needed. 
 
 Finally, answering the last questions, “Do you feel this contra stockholders’ equity method of accounting 
for R&D may allow U.S. companies to compete more effectively in the international market?”  42% of the respon-
dents answered yes, 54% no and 4% not sure.  Presumably, the respondents answering “yes” did so because they felt 
that the proposed method would provide an incentive for more to be spent on R&D or a shift in R&D to longer term 
projects or both. 
 
 A separate part of the questionnaire listed four proposed methods of reporting research and development 
expenditures in published financial statements.  After reading the four methods, respondents were asked to indicate 
on a scale, from 1-least appropriate, to 7-most appropriate how appropriate each method would be for their firm.  
The methods scored, respectively, as follows:  the expense-as-incurred method in practice, an average of 5.6; the 
proposed contra stockholders’ equity method, and average of 4; a capitalization and fixed write-off method, and av-
erage of 2.5; and a choice of either capitalization (shown as an asset) or charge to income as incurred, depending on 
estimates of future productiveness, an average of 2.6.  It is noteworthy that the proposed contra stockholder method 
scored almost as high as the expense-as-incurred method use in practice.  This is particularly so because the above 
numbers represent the averages for all respondents.  Figure 1. shows relative appropriateness of each of four possi-
ble methods of accounting for research and development costs as published financial statements. 
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A: Expense as Incurred 
B: Contra Stockholders’ Equity 
C: Capitalization and Fixed Write-off 
D: Choice of Either Expense or Capitalization 
 
Conclusions 
 
 Results from this study tentatively indicate that if the contra stockholders’ equity method were used for the 
financial reporting of R&D expenditures, a larger total dollar amount of R& D would be spent, a shift in total R&D 
toward longer projects would occur, U.S. companies would compete more effectively in the international market, 
and the relevancy of financial accounting earnings would be improved.  Thus, the expense-as-incurred method of 
accounting for R&D is impeding sound corporate R&D decision making. However, the respondents still selected 
that the most appropriate method of accounting for R&D is the expense-as-incurred method.  They indicated, in 
writing, a concern that a less favorable R&D tax policy could be the result of any change, but tax policy need not be 
changed. 
 
Suggestions for Future Research 
 
 Since R&D Expenditures are such an important component in business enterprise continued research into 
possible capitalization and future write-off of R&D should occur.  This additional research should be undertaken re-
garding the financial reporting of R & D expenditures, R & D tax policy, and the impact of the proposed contra-
stockholders’ equity method on company size within all industries.   
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